Annual Report

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

Essent Group boosts its dividend after a strong 2025, returning $700M to shareholders while making a strategic leap into the global P&C reinsurance market.

The retail REIT reports record-breaking leasing and strong profits for 2025, while executing a strategic portfolio overhaul and setting a confident tone for 2026.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

Skycorp Solar reported a 27% revenue surge driven by global expansion, but intense competition and rising costs led to a surprising net loss.

With major conferences ahead, clinical-stage MBX Biosciences aims to impress investors with its promising peptide therapies for endocrine and metabolic disorders.

TruGolf accelerates its stock repurchase program, signaling faith in its future as it unveils new AI-powered tech in a booming indoor golf market.

After a stellar 2025, Corpay is hitting the road for key investor conferences. Can it convince the market its impressive growth is just the beginning?

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

The private jet operator posted record revenue with fewer planes, achieving its first-ever quarter of positive Adjusted EBITDA in a major turnaround.

The high-tech wheel maker's stock plummets 65% as it fails to meet listing rules, signaling deep financial and operational distress for the company.

The semiconductor giant posted a huge Non-GAAP profit but a stunning IFRS loss for 2025. What's behind the numbers and why are investors cheering?

Life sciences giant QIAGEN defies economic headwinds with strong 2025 results, signaling aggressive growth in single-cell analysis and bioinformatics.

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

Flexible Solutions posts modest 2025 revenue gains, but a major strategic shift to food-grade products and new factories sets the stage for a breakout year.

As LandBridge prepares for its March Investor Day, all eyes are on its strategy to leverage Permian Basin acreage for both energy and digital growth.

As Cellebrite prepares to report its 2025 results, all eyes are on its performance as a key indicator for the future of AI in law enforcement and public safety.

A new PwC survey shows CEO optimism plummeting as most firms fail to monetize AI, while a select few reap huge rewards, widening a dangerous gap.

As Sherritt prepares its 2025 results, investors watch how it navigated volatile nickel and cobalt markets while its Cuban energy unit thrived.